Program
The program has been meticulously designed to serve as a platform for sharing the latest breakthroughs and insights in hematology. It encompasses a variety of engaging sessions that delve into the most advanced areas in hematological sciences, promising a rich and enlightening experience.
We invite you to join us on this journey of exploration and discovery, as we collectively strive to enhance our understanding and treatment of hematology conditions.
Session Highlights
Session I:
Bleeding
Session I will cover Hemophilia, rare bleeding disorders, and bleeding related to direct oral anticoagulants (DOACs).
Session II:
Thrombosis
Session II will discuss on the use of DOACs in Kidney disease, treatment of subsegmental pulmonary embolism and distal deep venous thrombosis.
Session III:
Hemoglobinopathies
Session III will provide insights into common hemoglobinopathies such as thalassemia and sickle cell disease, as well as discuss gene therapy and iron chelation for these conditions.
Session IV:
Consultative Hematology
Session IV will cover preoperative evaluation, FAQs, hematological emergencies, and gynaecological hematology scenarios.
Session V:
Acute leukemia
Session V will discuss on the latest advancements in the management & treatment of Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Session VI:
MPN/MDS
Session VI will cover the most recent objectives and guidelines regarding Chronic Myeloid Leukemia (CML), the diagnosis and treatment of Myelodysplastic/Myeloproliferative Neoplasms, and the hematological aspects of mastocytosis.
Session VII:
Lymphoma
Session VII will discuss on the recent update on MCL, DLBCL, Follicular lymphoma and CAR-T in lymphoma management.
Session VIII:
Cellular therapy/BMT
Blood and Marrow Transplant, and Cellular Therapy (HBC) session will discuss on the advanced treatment options with care and compassion.
Session IX
Paediatric hematology - Part I – Malignant
Paediatric hematologic malignancies are a heterogeneous group of cancers that begin in blood-forming tissue, such as cells formed in the bone marrow or cells of the immune system. The epidemiology, functional limitations and their treatments are addressed in this session.
Session X:
Paediatric Hematology - Part II – Benign
This session will provide a comprehensive overview of benign hematologic disorders in children. State-of-the-art information on pathophysiology, diagnosis, treatment, and management strategies.
Session XI:
Platelet disorders
The platelet disorder session will discuss on the Management of ITP in pregnancy, Congenital TTP and Transplant-associated thrombotic microangiopathy (TA-TMA).
Session XII:
Plasma Cell disorder
Session XI will discuss on the recent updates on diagnosis and management of multiple myeloma and immunotherapy in RR myeloma.
CME Accredation
Instructions for Claiming CME Certificates:
- Post the event, registered attendees will receive an online evaluation survey to their registered email address.
- Once the survey is completed, you will automatically receive the CME Certificate by email.
- Please ensure that the email address provided at the time of registration is accurate.
Disclosure and Resolution of Personal Conflicts of Interest
This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support.
Session Attendance Scanning :
- Attendance to the sessions will be monitored through scanning of the barcode on your conference badge at the entrance of the session hall.
- CME credits will be awarded in accordance with session attendance.
